Do research procedures pose relatively greater risk for healthy persons than for persons with schizophrenia?

Schizophrenia Bulletin

Volumn 32, Issue 1, 2006, Pages 153-158

  Roberts, Laura Weiss ^a   Dunn, Laura B ^b   Green Hammond, Katherine A ^c   Warner, Teddy D ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Informed consent; Institutional Review Board; Placebo research risk; Research ethics; Research safeguards

Indexed keywords

ADULT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PSYCHIATRIST; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

ADULT; BIOMEDICAL RESEARCH; FEMALE; HEALTH STATUS; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; MALE; SCHIZOPHRENIA;

EID: 30344432663     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbi055     Document Type: Review

References (32)

1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363:2063-2072.
2. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophrenia Bull 2004;30:279-293.
3. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatr 2005;10(1):79-104.
4. Carpenter WT. Clinical constructs and therapeutic discovery. Schizophr Res 2004;72:69-73.
5. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bull 2004;30:193-217.
6. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? J Amer Med Assoc 2000;283:2701-2711.
7. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Government Printing Office; 1979.
8. Pincus H, Lieberman J, Ferris S. Ethics in Psychiatric Research: A Resources Manual for Human Subjects Protection. Washington, DC: American Psychiatric Press; 1999.
9. Dresser R. Mentally disabled research subjects: the enduring policy issues. J Amer Med Assoc 1996;276:67-72.
10. Brody BA. The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press; 1998.
11. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard: Implications for pediatric research without a prospect of direct benefit. J Amer Med Assoc 2005;294:826-832.
12. Department of Health and Human Services. Code of Federal Regulations, Title 45: Public Welfare. Part 46: Protection of Human Subjects (Subpart C). Washington, DC: Government Printing Office; 1991.
13. Woodward B. Challenges to human subject protections in US medical research. J Amer Med Assoc 1999;282(20):1947-1452.
14. Silverman HJ, Luce JM, Schwartz J. Protecting subjects with decisional impairment in research: the need for a multifaceted approach. Am J Resp Crit Care 2004;169(1):10-14.
15. Silverman H, Hull SC, Sugarman J. Variability among Institutional Review Boards' decisions within the context of a multicenter trial. Crit Care Med 2001;29(2):235-241.
16. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D. How do Institutional Review Boards apply the federal risk and benefit standards for pediatric research? J Amer Med Assoc 2004;291:476-482.
17. Frank E, Novick DM, Kupfer DJ. Beyond the question of placebo controls: ethical issues in psychopharmacological drug studies. Psychopharmacology 2003;171:19-26.
18. Levine RJ. Ethics and Regulation of Clinical Research. Baltimore: Urban and Schwartzenberg; 1986.
19. Roberts LW, Roberts BD. Psychiatric research ethics: an overview of evolving guidelines and current ethical dilemmas in the study of mental illness. Biol Psychiat 1999;46:1025-1038.
20. Roberts LW. The ethical basis of psychiatric research: conceptual issues and empirical findings. Compr Psychiat 1998;39(3):99-110.
21. Appelbaum PS. Rethinking the conduct of psychiatric research. Arch Gen Psychiat 1997;54:117-120.
22. Carpenter W. The schizophrenia ketamine challenge study debate. Biol Psychiat 1999;46:1081-1091.
23. Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiat 1997;54:401-407.
24. Kim SYH. Benefits and burdens of placebos in psychiatric research. Psychopharmacology 2003;171:13-18.
25. Roberts LW, Warner TD, Nguyen KD, Geppert CM, Rogers MD, Roberts BD. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom reemergence during psychopharmacological research participation. Psychopharmacology 2003;171:58-67.
26. Roberts LW, Green Hammond KA, Warner TD, Lewis R. Influence of ethical safeguards on research participation: comparison of perspectives of people with schizophrenia and psychiatrists. Am J Psychiat 2004;161:2309-2311.
27. Roberts LW, Warner TD, Brody JL. Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiat 2000;157:67-74.
28. Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits? Nat Med 2004;10(6):570-573.
29. Roberts LW, Warner TD, Brody JL, Roberts B, Lauriello J, Lyketsos C. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiat 2002;159:573-584.
30. Warner TD, Roberts LW, Nguyen K. Do psychiatrists understand research-related experiences, attitudes, and motivations of schizophrenia study participants? Compr Psychiat 2003;44(3):227-233.
31. Sachs GA, Stocking CB, Stern R, Cox DM, Hougham G, Sachs RS. Ethical aspects of dementia research: informed consent and proxy consent. Clin Res 1994;42(3):403-412.
32. High DM. Research with Alzheimer disease subjects: informed consent and proxy decisionmaking. J Am Geriatr Soc 1992;40:950-957.